The Ultimate Solution Of Joint Pain Us-fda Approved Joint Pain Relieving Harbal “churna” For Osteoarthitis, Rheumatoid Arthritis, Spondilytis And Other Joint Pain | 50370
ISSN: 2167-0846

Journal of Pain & Relief
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

The ultimate solution of joint pain us-fda approved joint pain relieving harbal “churna” for osteoarthitis, rheumatoid arthritis, spondilytis and other joint pain

2nd International Conference and Exhibition on Pain Medicine

Sahil Patel

Pain Management, Gujarat, India

ScientificTracks Abstracts: J Pain Relief

DOI: 10.4172/2167-0846.C1.008

Objective: To find the effectiveness of the "Churna" as an alternative treatment to any invasion in joints for the Pain relief of Osteoarthritis, Rheumatoid arthritis and / or any kind of Joint Pain. Methodology: A study was carried out where 889 patients of Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spodylosis, and Chronic Spodylitis & Frozen Shoulder of age group between 29 to 94 yrs were given 10gms of sachets of the "Churna" two times a day for 12-15 month period. Mechanism of Action: This "Churna" containing 9 natural phytonutrients exerting synergistic activities on body, reducing inflammation and pain by inhibiting prostaglandin synthesis, suppressing cyclooxygenase-1, cyclooxygenase 2, 5-lipoxygenase and cytokines and neutralizing leukocyte elastase and free radicals by inhibiting lipid peroxidation and raising levels of Vitamin C. This "Chuma" promotes healing of joints by stimulating peripheral and collateral circulation, inhibiting platelets aggregation, reducing synovial fluid leucocyte count and lowering elevated serum transarninase levels and erythrocyte sedimentation rates, and supplying lysine to help maintain nitrogen balance in body. Results: Eleven out of 889 patients had partial pain relief around 30-50% with the "Churna" as they left the treatment in the middle of treatment period. Total 98.76 percentage of the patient who completed stydy period of 12-15 months exhibited complete pain relief on use of the "Churna" without any noticeable side effects. Conclusion: For painful joint treatments, Ozone treatment, LAHC injections, Prolotherapy requires invasion of joint and long term NSAID use has known systemic side effects. Here, simple oral intake of the "Churna" to relieve joint pain without any kind of joint invasion or visible systemic side effects was achieved successfully in 878 out of 889 patients proving its effectiveness.

Sahil Patel cleared his MBA for hospital administration (theory) from Indian school of business management and administration (Maharashtra govt.) In March 2008. He is the asst. Professor in dept. of anesthesiology, GAIMS, Bhuj from July 2011. He Runs a pain clinic since 2006 and treating patients with bachache, scietica, cervical spondylosis, migraine, cluster headache, frozen shoulder, cancer pain, painless labor (delivery without pain).

Email: [email protected]